Payment overview · 2025
General Payments
$817.70
32 reported records · 18 companies
Healthcare provider profile · identity verified
Samuel S Kuo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · TULARE, CA · NPI 1861478422
Verified facts
What the public records show
CMS Open Payments records show Samuel S Kuo, M.D. received $817.70 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Enhertu, Keytruda, Libtayo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENHERTU as an associated drug or biological on 13123 records involving 6425 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Enhertu by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEYTRUDA as an associated drug or biological on 46588 records involving 15767 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Keytruda by this doctor in 2024.
Regeneron Healthcare Solutions, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LIBTAYO as an associated drug or biological on 22545 records involving 10925 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Libtayo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $177.59 | 21.7% | 6 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $86.61 | 10.6% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $64.62 | 7.9% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $56.75 | 6.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $55.18 | 6.8% | 2 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.80 | 6.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.46 | 5.1% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $39.37 | 4.8% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $35.25 | 4.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $32.04 | 3.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.05 | 3.5% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.75 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.82 | 3.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.56 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.21 | 2.6% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $18.60 | 2.3% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.30 | 2.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.74 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $749.21 | 31 |
| Education | $68.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $86.61 | 4 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $68.49 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $64.62 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $56.75 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $55.18 | 2 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $54.59 | 2 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $48.80 | 2 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $39.66 | 2 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $35.25 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $33.05 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $33.05 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $32.04 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.05 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.05 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $25.05 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | AstraZeneca Pharmaceuticals LP | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENHERTU enhertu |
2025 | Enhertu | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEYTRUDA keytruda |
2025 | Keytruda | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LIBTAYO libtayo |
2025 | Libtayo | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | ENHERTU open payments reported associated product |
CMS Open Payments — General Payments 13123 supporting records · 6425 recipient NPIs · example record 1206131386 |
Enhertu · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | KEYTRUDA open payments reported associated product |
CMS Open Payments — General Payments 46588 supporting records · 15767 recipient NPIs · example record 1237992210 |
Keytruda · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Regeneron Healthcare Solutions, Inc. Exact reporting entity; no affiliate inference |
2025 | LIBTAYO open payments reported associated product |
CMS Open Payments — General Payments 22545 supporting records · 10925 recipient NPIs · example record 1212855234 |
Libtayo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 343 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 169 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 130 | 41 |
| Losartan Potassium | Losartan Potassium | 110 | 31 |
| Lisinopril | Lisinopril | 98 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 97 | 26 |
| Gabapentin | Gabapentin | 95 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 22 |
| Furosemide | Furosemide | 89 | 33 |
| Amoxicillin | Amoxicillin | 88 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 14 |
| Ibuprofen | Ibuprofen | 86 | 25 |
| Metformin Hcl | Metformin Hcl | 74 | 20 |
| Mirtazapine | Mirtazapine | 73 | 24 |
| Celecoxib | Celecoxib | 68 | 16 |
| Alprazolam | Alprazolam | 65 | 11 |
| Omeprazole | Omeprazole | 63 | 22 |
| Montelukast Sodium | Montelukast Sodium | 62 | 17 |
| Potassium Chloride | Potassium Chloride | 61 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 22 |
| Ondansetron Odt | Ondansetron | 55 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 20 |
| Famotidine | Famotidine | 51 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 51 | 16 |
| Anastrozole | Anastrozole | 48 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 12 |
| Eliquis | Apixaban | 42 | 11 |
| Buspirone Hcl | Buspirone Hcl | 41 | 12 |
| Tramadol Hcl | Tramadol Hcl | 39 | 17 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | 12 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | 24 |
| Fluconazole | Fluconazole | 34 | 12 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | 12 |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 23 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Exemestane | Exemestane | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 21 | suppressed |
| Keytruda | Pembrolizumab | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Enhertu | Fam-Trastuzumab Deruxtecn-Nxki | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Pomalyst | Pomalidomide | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Imbruvica | Ibrutinib | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Libtayo | Cemiplimab-Rwlc | 11 | suppressed |
| Lupron Depot | Leuprolide Acetate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Pegasys | Peginterferon Alfa-2a | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $817.70 · 32 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AKEEGA, BALVERSA, DANZITEN, ENHERTU, ERLEADA, FOTIVDA, IMFINZI, JAKAFI, JAYPIRCA, KEYTRUDA, KISQALI, LIBTAYO, LYNPARZA, Lenvima, MONJUVI, MOVANTIK, NERLYNX, Nubeqa, OJJAARA, OPDIVO, Onivyde, PYRUKYND, SCEMBLIX, VERZENIO, Vonjo, Xofigo | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Enhertu play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error